4-氯-6-甲硫基嘧啶 | 89283-48-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 4-氯-6-甲硫基嘧啶
• 中文别名: 4-氯-6-甲基硫代嘧啶
• 英文名称: 4-chloro-6-(methylthio)pyrimidine
• 英文别名: 4-Chloro-6-methylthiopyrimidine；4-chloro-6-methylsulfanylpyrimidine
• CAS: 89283-48-7
• 化学式: C₅H₅ClN₂S
• 分子量: 160.627
• InChiKey: BMQSAIGMUNXTKZ-UHFFFAOYSA-N

物化性质

• 熔点：
  50-51 °C
• 沸点：
  260 ºC
• 密度：
  1.37
• 闪点：
  111 ºC

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  51.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 安全说明：
  S36/37
• 危险类别码：
  R43
• WGK Germany：
  3
• 海关编码：
  2933599090
• 危险性防范说明：
  P280
• 危险性描述：
  H302,H317
• 储存条件：
  2-8°C

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4-Chloro-6-Methylthiopyrimidine
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Skin sensitisation (Category 1), H317
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
R43
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H317 May cause an allergic skin reaction.
Precautionary statement(s)
P280 Wear protective gloves.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 160,63 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4-Chloro-6-Methylthiopyrimidine
Acute Tox. 4; Skin Sens. 1; <= 100 %
H302, H317
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4-Chloro-6-Methylthiopyrimidine
Xn, R22R43 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
H317 May cause an allergic skin reaction.
Skin Sens. Skin sensitisation
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
R43 May cause sensitisation by skin contact.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  4-氯-6-甲硫基嘧啶 在 磺酰氯 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 0.5h， 以76%的产率得到4,6-二氯嘧啶
  参考文献：
  名称：

  用硫酰氯对嘧啶环系统上的甲基硫烷基进行有效的一步氯化

  摘要：

  使用乙腈/二氯甲烷中的硫酰氯，可轻松实现嘧啶环系统上甲基硫烷基和芳基硫烷基的一步式转化为相应的氯基。

  DOI：

  10.1016/j.tetlet.2010.06.056
• 作为产物：
  描述：

  4,6-二氯嘧啶 、 sodium thiomethoxide 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 4-氯-6-甲硫基嘧啶
  参考文献：
  名称：

  使用苯甲酮作为介体通过光诱导偶联合成烷基化嘧啶

  摘要：

  烷基化嘧啶的合成是通过二苯甲酮介导的饱和杂环与磺酰基嘧啶之间的光诱导偶联来实现的。嘧啶环被选择性地引入杂原子（包括氧，氮和硫）附近的非酸性C（sp 3）–H键。这是仅由光激发的二苯甲酮（一种有机分子）介导的偶联反应，无需任何金属催化剂或试剂的帮助。

  DOI：

  10.1021/acs.joc.6b03058

文献信息

• Chemoselective Reactions of 4,6-Dichloro-2-(methylsulfonyl)pyrimidine and Related Electrophiles with Amines
  作者：Young-Choon Moon、Ramil Baiazitov、Wu Du、Chang-Sun Lee、Seongwoo Hwang、Neil Almstead

  DOI：10.1055/s-0033-1338853

  日期：——

  Chemoselective SNAr reactions of 4,6-dichloro-2-(methylsulfonyl)pyrimidine and several related electrophiles with amines and their derivatives are described. In the presence of weak bases anilines and secondary aliphatic amines selectively displace the chloride group. Deprotonated anilines and their carbonyl derivatives displace the sulfone group. Sterically and electronically unbiased primary aliphatic amines

  献给斯科特E.丹麦教授在他的60之际个生日 抽象 描述了4,6-二氯-2-（甲基磺酰基）嘧啶和几种相关亲电试剂与胺及其衍生物的化学选择性S NAr反应。在弱碱的存在下，苯胺和脂肪族仲胺选择性取代氯基。去质子化的苯胺及其羰基衍生物取代了砜基。立体和电子无偏伯脂肪族胺选择性取代4,6-二氯-2-（甲基磺酰基）嘧啶中的砜基；然而，它们与其他亲电试剂的反应通常选择性较低。提出了立体驱动的选择性解释。 描述了4,6-二氯-2-（甲基磺酰基）嘧啶和几种相关亲电试剂与胺及其衍生物的化学选择性S NAr反应。在弱碱的存在下，苯胺和脂肪族仲胺选择性取代氯基。去质子化的苯胺及其羰基衍生物取代了砜基。立体和电子无偏伯脂肪族胺选择性取代4,6-二氯-2-（甲基磺酰基）嘧啶中的砜基；然而，它们与其他亲电试剂的反应通常选择性较低。提出了立体驱动的选择性解释。
• [EN] GCN2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GCN2 ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2019148132A1

  公开（公告）日：2019-08-01

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• 作为FGFR4抑制剂的杂环化合物
  申请人：齐鲁制药有限公司

  公开号：CN112341431A

  公开（公告）日：2021-02-09

  本发明提供了作为成纤维细胞生长因子受体4(FGFR4)选择性抑制剂的杂环化合物，含有所述化合物的药物组合物，所述化合物的制备方法和以及利用本发明化合物治疗细胞增殖性疾病，例如癌症的方法。
• [EN] PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS<br/>[FR] PYRAZOLO[1,5-A]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE JAK2
  申请人：VERTEX PHARMA

  公开号：WO2009085913A1

  公开（公告）日：2009-07-09

  The present invention relates to compounds of formula (I) useful as selective inhibitors of JAK2 kinase. The invention also provides pharmaceutical acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various diseases, conditions or disorders. The invention also provides processes for preparing the compounds of the invention.

  本发明涉及作为JAK2激酶选择性抑制剂的化合物(I)的公式，还提供包含所述化合物的药用合适组合物以及使用这些组合物治疗各种疾病、症状或紊乱的方法。该发明还提供了制备本发明化合物的方法。
• [EN] INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR<br/>[FR] MODULATEURS INDOLES ET AZAINDOLES DU NACHR-?7
  申请人：PROXIMAGEN LTD

  公开号：WO2011045353A1

  公开（公告）日：2011-04-21

  This invention relates to modulation of the α7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I) or a pharmaceutically acceptable salt thereof.

  这项发明涉及利用式(I)的化合物或其药用可接受盐对α7尼古丁乙酰胆碱受体(nAChR)进行调节。